A5013274382- Prostate Cancer Treatment and Research
- Hormonal and reproductive studies
- Cancer, Lipids, and Metabolism
- Kruppel-like factors research
- RNA regulation and disease
- Genomics, phytochemicals, and oxidative stress
- Prostate Cancer Diagnosis and Treatment
- Nuclear Receptors and Signaling
- RNA modifications and cancer
- Circular RNAs in diseases
- GDF15 and Related Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Sirtuins and Resveratrol in Medicine
- Cancer-related molecular mechanisms research
- Inflammatory mediators and NSAID effects
- Genetic factors in colorectal cancer
- CRISPR and Genetic Engineering
- Cancer Genomics and Diagnostics
- Cytokine Signaling Pathways and Interactions
- Ubiquitin and proteasome pathways
- Estrogen and related hormone effects
- Mass Spectrometry Techniques and Applications
- interferon and immune responses
- Bone Metabolism and Diseases
- Protein Kinase Regulation and GTPase Signaling
National Cancer Institute
2018-2024
Center for Cancer Research
2021-2023
National Institutes of Health
2019-2022
Cancer Institute (WIA)
2019
University of Tennessee at Knoxville
2007-2012
Knoxville College
2007-2011
National Institute of Environmental Health Sciences
2011
University of Tennessee System
2008
Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) shown lower rates recurrence among patients minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor are not known. To identify genomic and histologic associated treatment resistance at baseline. Targeted biopsies were obtained 37 men intermediate- to high-risk before...
Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease before treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely to harbor aggressive disease.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to prevent colorectal tumorigenesis. Although antitumor effects of NSAIDs mainly due inhibition cyclooxygenase activity, there is increasing evidence that cyclooxygenase-independent mechanisms may also play an important role. The early growth response-1 (EGR-1) gene a member the immediate-early family and has been identified as tumor suppressor gene. Tolfenamic acid NSAID exhibits anticancer activity in pancreatic cancer model. In...
Resveratrol, a dietary phytoalexin readily available in the diet, is reported to possess antitumorigenic properties several cancers, including colorectal. However, underlying mechanism(s) involved not completely understood. In present study, we investigated effect of resveratrol treatment on gene modulation human colorectal cancer cells and identified activating transcription factor 3 (ATF3) as most highly induced after treatment. We confirmed that upregulates ATF3 expression, both at mRNA...
Abstract Purpose: Therapies targeting the androgen receptor (AR) have improved outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker AR-targeted therapy resistance in castration-resistant (CRPC), but its importance CSPC remains understudied. Experimental Design: We assessed different approaches to quantify AR-V7 mRNA and protein cell lines, patient-derived...
Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst well-characterized drivers of tumorigenesis. Canonically, up-regulation luminal cells functions to oppose terminally differentiating effects AR. However, are pleiotropic inconsistent a poorly proliferative phenotype. Here we show that increased expression activity associated down-regulation MEIS1, HOX-family factor. Using RNA-seq profile series human specimens...
ABSTRACT Despite decreased screening-based detection of clinically insignificant tumors, most diagnosed prostate cancers are still indolent, indicating a need for better strategies significant disease prior to treatment. We hypothesized that patients with detectable circulating tumor DNA (ctDNA) were more likely harbor aggressive disease. applied ultra-low pass whole genome sequencing profile cell-free from 112 localized cancer and performed targeted resequencing plasma somatic mutations...
ABSTRACT Localized prostate cancer is distinctively characterized by intratumoral heterogeneity, and tumors with more complex evolutionary paths display aggressive characteristics. In clinical trials of intense neoadjuvant androgen deprivation therapy (inADT), patients complete or near-complete responses experience durable remissions. However, the molecular characteristics distinguishing exceptional responders nonresponders at baseline have not been established. Here, we present integrated...
Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected the final prostatectomy specimen. Accurate identification and measurement residual tumor volumes critical for tracking stratifying patient outcomes.The goal this current study was to evaluate ability antibodies against prostate-specific membrane antigen (PSMA) specifically detect cohort 35 patients treated with iADT plus enzalutamide 6 months prior radical...
Prostate cancer incidence in young men has increased. Patients diagnosed at an earlier age are likely to have aggressive prostate and treatment decisions continuing be weighted by patient life expectancy. Identification of age-associated gene-expression signatures hold great potential augment current future modalities. To investigate age-specific tumor associated gene their biomarkers for disease aggressiveness, this study was designed stratified into well poorly differentiated types (42–58...
Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition definitive treatment. Sufficient profiling baseline has remained a challenge in enabling in-depth assessment phenotypes associated exceptional vs. poor pathologic responses after In this study, we report comprehensive integrative gene expression 37 locally advanced tumors...
Abstract Background Therapies targeting the androgen receptor (AR) have improved outcome for patients with castration-sensitive prostate cancer (CSPC). Expression of constitutively active AR splice variant-7 (AR-V7) has shown clinical utility as a predictive biomarker AR-targeted therapy resistance in castration-resistant (CRPC), but its importance CSPC remains understudied. Methods We explored multiple approaches to quantify AR-V7 mRNA and protein cell lines patient-derived xenograft (PDX)...
Abstract Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic properties in animal vitro models of cancer. However, the underlying cellular mechanisms by which TA exerts its effects are only partially understood. Activating transcription factor 3 (ATF3) member ATF/CREB subfamily basic region-leucine zipper family has been known as tumor suppressor human colorectal cancer cells. The present study was performed to observe whether...
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer
Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker Clinical Response in Castration-Sensitive Prostate Cancer